Jefferies lowered the firm’s price target on Sanofi to $63 from $64 and keeps a Buy rating on the shares. Into Q4 earnings for European pharma, the firm is most comfortable with Novartis and GSK as the firm’s estimates are above consensus. Jefferies also forecasts a Sanofi profit beat.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNY:
- Sanofi price target raised to EUR 105 from EUR 95 at Barclays
- Sanofi upgraded to Outperform from Peer Perform at Wolfe Research
- AstraZeneca (NASDAQ:AZN) Gains on New Drug
- Exscientia expands Sanofi deal, eligible for $45M in milestones plus incentives
- Sanofi discontinuing tusamitamab ravtansine after trial did not meet endpoint